Healthy Extracts Reports Record 2024 Financial Results, Driving First-Ever Positive Adj. EBITDA of $0.02 Per Share

Rhea-AI Summary

Healthy Extracts (OTCQB:HYEX) reported strong financial results for 2024, with net revenue increasing 25% to $3.1 million. The company achieved its first-ever positive Adjusted EBITDA of $61,000 ($0.02 per share) and generated positive operating cash flow of $282,000.

Key financial metrics include:

• Gross profit up 18% to $1.9 million (61.4% margin)
• Operating expenses decreased 46% to $2.1 million
• Net loss reduced to $841,000 ($(0.28) per share)

Operational highlights include a 72% increase in direct-to-consumer subscription customers and 77% growth in Amazon Subscribe & Save customers. The company achieved record Amazon sales, ranking in the top three of its category. For 2025, HYEX projects revenue growth of 29%+ to over $4.0 million, driven by new product launches including sugar blockers, hydration solutions, and heart health formulations.

Positive

• First-ever positive Adjusted EBITDA of $61,000 ($0.02 per share)
• Net revenue increased 25% to $3.1 million
• Generated positive operating cash flow of $282,000
• Operating expenses decreased 46% to $2.1 million
• Subscription customer base grew over 70% year-over-year
• Customer churn rate reduced from 5% to under 3%

Negative

• Net loss of $841,000 despite improvements
• Gross margin declined to 61.4% from 65.2% due to lower-margin products

Net Revenue up 25%, with Strong Subscription-Based Recurring Revenue Growth Helping to Drive Positive Cash Flow and First-Ever Positive Adjusted EBITDA

Outlook for Accelerating Net Revenue Growth in 2025, Projected up 29%+

LAS VEGAS, NEVADA / ACCESS Newswire / April 1, 2025 / Healthy Extracts Inc. (OTCQB:HYEX), an innovative platform for acquiring, developing, patenting, marketing and distributing plant-based nutraceuticals, reported results for the year ended December 31, 2024. All comparisons are to the year-ago period unless otherwise noted.

2024 Financial Highlights

• Net revenue increased 25% to a record $3.1 million, driven by product line and distribution channel expansion as well as growth in subscription-based recurring revenue.

• Gross profit increased 18% to $1.9 million or 61.4% of net revenue, compared to $1.6 million or 65.2% of net revenue.

• Operating expenses decreased 46% to $2.1 million.

• Net loss decreased to $841,000 or $(0.28) per basic and diluted share from a net loss of $2.5 million or $(0.85) per basic and diluted share in 2023.

• Adjusted EBITDA totaled $61,000 or $0.02 per share, turning positive from an adjusted EBITDA loss of $456,000 or $(0.16) per share in 2023 (see definition of adjusted EBITDA, a non-GAAP term, and its reconciliation to GAAP, below).

• Generated positive operating cash flow of $282,000 versus negative cash flow in 2023.

• Direct-to-consumer subscription-based customers increased 72% year-over-year and Amazon "Subscribe & Save" customers increased 77% year-over-year. In addition to the benefits of recurring revenue, subscriptions help the company enhance customer communications, improve customer retention and extend customer lifetime value.

2024 Operational Highlights

• Record Amazon sales were reflected in the company's top three category ranking, with this due to the company's highly optimized sales and marketing strategies.

• Officially launched LONGEVITY Anti-Aging™, a new proprietary formulation designed to support skin vitality, arterial flexibility, and cellular and joint health.

• Advanced the development of several new products across new categories that are planned for launch in 2025 and expected to benefit from the company's growing customer base.

• In July 2024, the company transitioned its customer communications program and product promotions from "buy-two-get-one-free" to a direct-to-consumer subscription-based model. As a result, during the second half of 2024, the company reduced its customer churn rate from 5% to under 3%, dramatically below the nutritional supplement industry average.

Management Commentary

"Our record-breaking revenue in 2024, which drove positive operating cash flow and first-ever positive adjusted EBITDA, reflects Healthy Extract's strong performance across direct-to-consumer channels and growing momentum with our retail partners," commented Healthy Extracts president, Duke Pitts.

"Our record Amazon sales raised us to a top three ranking in our category, with this success attributed to our well-tuned marketing efforts. The top line growth was also driven by our growing subscription sales, broadened distribution channels, and new product offerings.

"After years of research and development, we will soon introduce several new products across new product categories. These new products will enable us to cross promote to our existing sales channels for the first time in our history and drive a substantial increase in revenue in 2025.

"Four new products are currently set to launch before the end of the second quarter, with this followed by additional releases later in the year. We expect these new products to have a very meaningful impact on our revenue growth and profitability.

"The near-term lineup includes a groundbreaking, on-the-go hydration solution, an easy-to-consume sugar blocker, and a convenient gel pack for gut health and anti-aging. However, perhaps most exciting of all is a revolutionary heart health formulation that will provide a long-needed solution to the more than 40 million statin users in the U.S. We plan to cross-promote across these product categories, thereby driving even greater sales.

"We believe our focused commitment to customer retention, product excellence, innovation, and strategic engagement continues to differentiate our brands from the competition. We have successfully leveraged our expertise to drive sales in key channels such as Amazon, where each new product launch presents the opportunity to drive millions in additional annual sales.

"We began the new year with solid cash flow, manageable debt, and a highly favorable capitalization structure. This strengthens our ability to pursue certain opportunistic M&A opportunities, as well as positions us for another year of record growth and increase in shareholder value."

2025 Outlook

For full year 2025, the company expects to remain on track for net revenue at more than $4.0 million, up 29%+ over 2024. New product launches across new categories and formats that are scheduled for throughout the year are expected to continue driving growth momentum and greater profitability (excluding non-cash-based expenses). The company plans to drive future growth by reinvesting its profits into new product development and channel expansion.

Product Outlook

Healthy Extracts' BergaMet is planning to launch several new product introductions in April:

• MYNUS sugar blocker, which is specially formulated to reduce up to 42% of the sugar impact from meals. The MYNUS on-the-go gel-packs will be made available under the company's exclusive U.S. and Canadian licensing and manufacturing agreement with Gelteq.

• Hydrate EZ: on-the-go gel pack specially formulated to provide hydration, focus, recovery, and sleep benefits without the need for mixing.

• Revolutionary heart health formulation targeting the more than 40 million statin users in the U.S.

Healthy Extracts' top brand ambassador and renowned fitness expert, Whitney Johns, is preparing to launch WHITNEY JOHNS™ NUTRITION on-the-go gel packs for gut health in the second quarter of 2025.

In the second half of the year, the company plans to launch COLLAGEN (anti-aging) in an on-the-go gel pack. These gel products will be based on Healthy Extracts' exclusive oral delivery system and proprietary formulations.

2024 Financial Summary

Net revenue in the full year of 2024 increased 25% to $3.1 million from $2.5 million in 2023, primarily due to product line and distribution channel expansion.

Gross profit increased to $1.9 million or 61.4% of net revenue from $1.6 million or 65.2% of net revenue in 2023. The decrease in gross margin was a result of a shift to lower margin products.

Operating expenses decreased 46% to $2.1 million as compared to $3.9 million in 2023.

Net loss totaled $841,000 or $(0.28) per basic and diluted share, as compared to a net loss of $2.5 million or $(0.85) per basic and diluted share in 2023. The improvement in net loss was primarily due to one-time costs associated with planned acquisitions, related public offering and uplist to major exchange that did not reoccur in 2024.

Adjusted EBITDA totaled $61,000 or $0.02 per share, turning positive from an adjusted EBITDA loss of $456,000 or $(0.16) per share in 2023.

About Healthy Extracts "Live Life Young Again"

Healthy Extracts Inc. is a platform for acquiring, developing, researching, patenting, marketing, and distributing plant-based nutraceuticals.

The company's subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement distributed in North America containing Citrus Bergamot SuperFruit™. This superfruit has the highest known concentration of polyphenols and flavonoids.

UBN's KETONOMICS® proprietary formulations, which have been designed to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities.

For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com.

Forward-Looking Statements and Safe Harbor Notice

All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2024, and future periodic reports filed with the SEC. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.

Use of Non-GAAP Measures

This press release contains financial measures that are not recognized measures under accounting principles generally accepted in the United States of America ("GAAP"), which are EBITDA and adjusted EBITDA. EBITDA is defined for the purposes of this press release as net income before Income tax expense, Interest expense, depreciation and amortization. Adjusted EBITDA is defined as EBITDA excluding the gain or loss related to stock-based option/warrant expense, change in fair value of derivative, and offering costs.

Healthy Extracts' management believes that EBITDA and adjusted EBITDA are useful supplemental measures of our operating performance and provide our investors meaningful measures of overall corporate performance. EBITDA is also presented because management believes that it is frequently used by investment analysts, investors, and other interested parties as a measure of financial performance. Adjusted EBITDA is also presented because management believes that it provides our investors additional measures of our core business. However, non-GAAP measures do not have a standardized meaning prescribed by GAAP, and investors are cautioned that non-GAAP measures, such as EBITDA and adjusted EBITDA, should not be construed as an alternative to net income or loss or other income statement data (which are determined in accordance with GAAP) as an indicator of our performance or as a measure of liquidity and cash flows. Management's method of calculating EBITDA and adjusted EBITDA may differ materially from the method used by other companies and, accordingly, may not be comparable to similarly titled measures used by other companies. A reconciliation of EBITDA and adjusted EBITDA to net income, the most comparable GAAP measure, is included in the table below. See the table, Consolidated Statement of Operations, provided further below for the weighted average number of common shares used for the determination of adjusted EBITDA basic and diluted earnings per common share.

		For the Twelve Months Ended
		December 31,
		2024				2023
Net Income		$	(840,671	)		$	(2,472,931	)
Income tax expense			-				-
Interest expense, net of interest income			186,252				176,948
Depreciation and amortization			(139	)			2,195
EBITDA			(654,558	)			(2,293,788	)
Stock-based option/warrant expense			241,858				1,494,191
Change in fair value of derivative			471,270				52,140
Offering costs			2,657				291,955
EBITDA adjustments			715,785				1,838,286
Adjusted EBITDA		$	61,227			$	(455,502	)
Adjusted EBITDA per common share - basic and diluted		$	0.02			$	(0.16	)

Food & Drug Administration Disclosure

The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor's advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™

Company Contact

Duke Pitts, President
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact

Investor Contact

CMA Investor Relations
Tel (949) 432-7554
Email contact

HEALTHY EXTRACTS INC.
CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE TWELVE MONTHS ENDING DECEMBER 31, 2024 AND 2023
(Audited)

		FOR THE TWELVE MONTHS ENDING DECEMBER 31,
		2024				2023
REVENUE
Revenue		$	3,113,279			$	2,485,866
Net revenue			3,113,279				2,485,866
COST OF REVENUE
Cost of goods sold			1,201,959				864,055
Total cost of revenue			1,201,959				864,055
GROSS PROFIT			1,911,320				1,621,810
OPERATING EXPENSES
General and administrative			2,094,469				3,865,654
Total operating expenses			2,094,469				3,865,654
OTHER INCOME (EXPENSE)
Interest expense, net of interest income			(186,252	)			(176,948	)
Change in fair value on derivative			(471,270	)			(52,140	)
Total other income (expense)			(657,522	)			(229,088	)
Net income/(loss) before income tax provision			(840,671	)			(2,472,931	)
NET INCOME/(LOSS)		$	(840,671	)		$	(2,472,931	)
Income/(Loss) per share - basic and diluted		$	(0.28	)		$	(0.85	)
Weighted average number of shares outstanding - basic and diluted			2,978,540				2,915,410

HEALTHY EXTRACTS INC.
CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2024 AND DECEMBER 31, 2023
(Audited)

		DECEMBER 31,				DECEMBER 31,
		2024				2023
ASSETS
CURRENT ASSETS
Cash		$	112,020			$	19,441
Accounts receivable			11,003				30,440
Deposit			16,890				-
Inventory, net			1,361,216				1,626,283
Offering costs			149,274				151,931
Right of use asset, net			8,984				71,583
Total current assets			1,659,387				1,899,678
Fixed assets			3,445				3,306
Patents/Trademarks			521,881				521,881
Deposit			-				16,890
Goodwill			193,260				193,260
Total other assets			718,586				735,336
TOTAL ASSETS		$	2,377,973			$	2,635,014
LIABILITIES AND STOCKHOLDERS' EQUITY
LIABILITIES
Accounts payable		$	52,248			$	116,842
Accrued liabilities			248,609				215,069
Lease liabilities - current			9,222				65,229
Lease liabilities - long-term			-				9,222
Notes payable			2,427				361,093
Notes payable - related party			399,388				83,366
Convertible debt, net of discount			530,860				608,601
Accrued interest payable			67,770				64,386
Accrued interest payable - related party			31,652				2,465
Derivative liabilities			625,420				154,150
Total current and total liabilities			1,967,596				1,680,424
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding, respectively			-				-
Common stock, $0.001 par value, 50,000,000 shares authorized, 2,989,406 shares issued and outstanding as of December 31, 2024, and 2,954,104 shares issued and outstanding as of December 31, 2023, respectively-			354,532				354,492
Additional paid-in capital			19,301,589				18,999,770
Treasury stock, at cost, 4,166 shares, respectively			(5,400	)			-
Accumulated deficit			(19,240,344	)			(18,399,673	)
Total stockholders' equity			410,377				954,590
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		$	2,377,973			$	2,635,014

SOURCE: HEALTHY EXTRACTS INC.

View the original press release on ACCESS Newswire

FAQ

What was Healthy Extracts (HYEX) revenue growth in 2024?

HYEX achieved 25% revenue growth in 2024, reaching $3.1 million compared to $2.5 million in 2023.

How much did HYEX's subscription-based customers grow in 2024?

Direct-to-consumer subscription customers increased 72% and Amazon Subscribe & Save customers grew 77% year-over-year.

What is Healthy Extracts' (HYEX) revenue projection for 2025?

HYEX projects revenue to exceed $4.0 million in 2025, representing growth of over 29% compared to 2024.

How did HYEX's profitability improve in 2024?

HYEX achieved its first-ever positive Adjusted EBITDA of $61,000 ($0.02 per share) and reduced net loss to $841,000 from $2.5 million in 2023.

What new products is HYEX launching in 2025?

HYEX plans to launch MYNUS sugar blocker, Hydrate EZ gel packs, a heart health formulation for statin users, and WHITNEY JOHNS NUTRITION gut health gel packs.